NewHavenBIZ

n e w h a v e n b i z . c o m | J u n e 2 0 2 1 | n e w h a v e n B I Z 9 EMCOR SERVICES NEW ENGLAND MECHANICAL We'll be there when you need us. With 50+ years of experience and more than 300 continuously trained, licensed, and certified facilities services technicians, we provide a wide range of building construction and facilities solutions across New England. COUNT ON NEMSI FOR: HVAC, Plumbing and Process Piping Design-Build Construction Electrical Services Energy Management Systems LEED Certification Programs Comprehensive Preventive Maintenance Programs 24/7/365 Emergency Response Call 860.871.1111 Toll Free 800.741.6367 Fax 866.481.3250 55 Gerber Road East, South Windsor, CT 06074 nemsi.com OFFICES IN Trumbull | New London | Palmer, MA | Albany, NY | Manchester, NH License #s: E1-0125666 • S1-302974 • P1-203519 • F1-10498 • SM1-192 • MC-1134 vivo, that tau was degraded. We are also looking at Parkinson's and other neurodegenerative diseases. ey are earlier in the pipeline compared to our oncology programs, so we expect to be in the clinic sometime next year. Where would you like the company to be in five years? 10 years? Over the next five years, if all goes well, we should have two products on the mar- ket, if they pass all of their hurdles. We will hopefully have the rest of our pipeline com- ing to fruition as well. We will have moved to our new building and will have grown. Over 10 years, we will continue to build. My wish would be that we will see the first neurodegenerative disease drugs that really work for people. If that is the case, then that will be exceptional — obviously for patients but also for the growth of the company. We see ourselves staying in Connecticut. We have no rationale to move out. As we get bigger, we may have to think of our tri- als globally. When you do trials outside the U.S., you need branches in different parts of the world. But our headquarters and where we are centered, and where we are excited to be, is Connecticut and the Greater New Haven area. Arvinas has a unique culture, with team- building activities. How did that get started, and what has it meant for the company's atmosphere? is has all been coming from the ground up, not from the top down. ey formed a fun committee. We have hiking and cooking classes, a book reading club. For every new employee who comes in, they have to tell two truths and a lie about themselves, and everyone has to guess and vote. at is always great fun. Because of the pandemic, keeping that culture going has been difficult. As more of the staff gets vaccinated, we will have more interactions. Annual revenues? We have no revenue — we have no products in the market. We pull in money by getting investors. At the end of last year, we had roughly $700 million in cash and cash equivalents in the bank, so that gives us quite a significant runway over the next few years. Do you envision Arvinas staying an independent company? Yes. Our plan is to continue to build the company all the way through to commercial launch. We will continue to grow and build the organization as an independent biotech. Do you think it will ever be acquired by a big pharma company? When you are in the biotech world and have exciting compounds, and they are helping patients, big pharma companies are always going to be looking to see whether that would be a fit for them. We are not looking to be acquired, because we think we can build a lot of value ourselves. But you also have to be cognizant of the fact that big pharma companies might be interested. Our game plan is to just continue to build the company. What are the biggest challenges the company faces? ere are natural research and develop- ment challenges. We're in novel science. Everything we are doing in the clinic is the first time it has ever been done. All the data we get is interesting, new and novel. So far that has been all positive, which is great, but you worry about that aspect. e other piece is just keeping the company moving forward. If we keep on this path, in terms of the exciting science, and being able to continue to recruit really good scientists, clinicians and leaders, I think we will be in a very good position for the next several years. n

• Cover